Could common diabetes drugs tame Post-Heart attack inflammation?

NCT ID NCT07295223

Recruiting now Disease control Sponsor: Instituto Mexicano del Seguro Social Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether two diabetes drugs—dapagliflozin and semaglutide—can reduce inflammation after a heart attack. Researchers will enroll 44 people with type 2 diabetes, obesity, and high inflammation levels. Participants will take one of the drugs for 24 weeks, and the study will measure changes in inflammatory markers like hs-CRP and IL-6.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dapagliflozin and semaglutide
What this could lead to: If it works, this could point toward a new way to lower harmful inflammation after a heart attack, potentially reducing long-term complications.
What could go wrong: This is a small pilot study with only 44 participants, so results may not apply widely. Past trials of similar drugs after heart attack did not meet their main goals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYOCARDIAL INFARCTION WITH ST ELEVATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ST-elevation myocardial infarction type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYOCARDIAL INFARCTION WITH ST ELEVATION

Contacts and locations

Locations

Hospital de Especialidades No.1, Centro Médico Nacional del Bajío
RECRUITING

León, Guanajuato, 37320, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.